Rational pharmacotherapy in the diabetic hypertension: Analysis-prescribing patterns in a general hospital in Taiwan

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 6, 2004, Pages 547-558

  Cheng, S F ^a,b   Hsu, Hsi Hsien ^b,c   Lee, H S ^b   Lin, C S ^b   Chou, Y C ^a   Tien, J H ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Drug utilization; Hypertension; Prescription analysis

Indexed keywords

ACARBOSE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GUAR GUM; HYDROCHLOROTHIAZIDE; INSULIN; LABETALOL; LISINOPRIL; METFORMIN; NIFEDIPINE; PERINDOPRIL; PRAZOSIN; RAMIPRIL; UNINDEXED DRUG; VASODILATOR AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC HYPERTENSION; DOSE CALCULATION; DRUG UTILIZATION; FEMALE; GENERAL HOSPITAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; STATISTICAL ANALYSIS; TAIWAN;

AGED; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, TEACHING; HOSPITALS, URBAN; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; TAIWAN;

EID: 10844232895     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00599.x     Document Type: Article

References (40)

1. Al Khaja KA, Sequeira RP, Mathur VS (2001) Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain. The Annals of Pharmacotherapy, 35, 1350-1359.
2. Evans JM, MacDonald TM, Leese GP, Luta DA, Morris AD (2000) Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care, 6, 770-774.
3. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
4. Kiloc C, Meenan A, Bloomgarden Z (1992) Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clinical Therapeutics, 14, 801-812.
5. Kramer W, Muller G, Girbig F et al. (1995) The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Research and Clinical Practice, 28 (Suppl.), S67-S80.
6. Campbell DB, Lavielle R, Nathan C (1991) The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Research and Clinical Practice, 14, S21-S36.
7. Holmes B, Heel RC, Brogden RN, Speight TM, Avery GS (1984) Gliclazide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs, 27, 301-327.
8. Scott R, Lintott CJ, Zimmet CL, Bowen KW Welbom T (1993) Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Research and Clinical Practice, 43, 179-185.
9. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. The Journal of the American Medical Association, 287, 360-372.
10. Salo S, Groop L (1988) Combination of two sulfonylureas. Does it make sense? Diabetes Care, 11, 751-753.
11. Shank M, Del PS, DeFronzo RA (1995) Bedtime insulin daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes, 44, 162-172.
12. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 355, 253-259.
13. UK Prospective Diabetes Study Group (1998) Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. British Medical Journal, 317, 720-726.
14. Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351, 1755-1762.
15. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine, 338, 645-652.
16. Tatti P, Pahor M, Byington R, Di Mauro P, Guarisco R, Strollo G, Strollo F (1998) Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 21, 597-603.
17. Psaty B, Heckbert SR, Koepsell TO et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. The Journal of the American Medical Association, 274, 620-625.
18. Grossman E, Messerli FH, Grodzicki T, Kowey P (1996) Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?. The Journal of the American Medical Association, 276, 1328-1331.
19. Velussi M, Brocco E, Frigato F et al. (1996) Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes, 45, 216-222.
20. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine, 329, 1456-1462.
21. Bretzel RG (1997) Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients? Journal of Hypertension, 15, S83-S88.
22. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. British Medical Journal, 317, 713-720.
23. Vijan S, Hayward RA, Rodney A (2003) Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Annals of Internal Medicine, 7, 593-602.
24. Messerli FH, Grossman E, Goldbourt U (1998) Are beta-blockers efficacious as first-line therapy for hypertension in the elderly. The Journal of the American Medical Association, 279, 1903-1907.
25. Amery A, Fagard R, Lijnen P, Reybrouck T (1977) Atenolol and plasma renin concentration in hypertensive patient. Postgraduate Medicine, 53 (Suppl. 3), 116-119.
26. Tyrer P (1988) Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs, 36, 773-783.
27. World Health Organization - International Society of Hypertension (1999) Guidelines for the management of hypertension. Guidelines Subcommittee. Journal of Hypertension, 17, 151-183.
28. MacLeod MJ, McLay J (1998) Drug treatment of hypertension complicating diabetes mellitus. Drugs, 56, 189-202.
29. Ames RP (1986) The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics. Drugs, 32, 260-278.
30. Savage PJ, Pressel SL, Curb JD et al. (1998) Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine, 158, 741-751.
31. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED (1998) Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Archives of Internal Medicine, 159, 551-558.
32. Curb JD, Pressel SL, Cutler JA et al. (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. The Journal of the American Medical Association, 276, 1886-1892.
33. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) (1999). Archives of Internal Medicine, 157, 2413-2446.
34. Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Archives of Internal Medicine, 156, 286-289.
35. Remuzzi G, Ruggeneti P, Benigmi A (1997) Understanding the nature of renal disease progression. Kidney, 51, 2-15.
36. Lindholm LH, Ibsen H, Dahlof B et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359, 1004-1010.
37. Epstein M, Bakris GL (1996) Newer approaches to antihypertensive therapy: use of fixed dose combination therapy. Archives of Internal Medicine, 156, 1969-1978.
38. Bakris GL, Weir MR, DeQuattro V, McMahon FG (1998) Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney International, 54, 1283-1289.
39. Dahlof B, Hosie J (1990) Antihypertensive efficacy and tolerability of a fixed combination of metoprololm and felodipine in comparison with the individual substances in monotherapy. Journal of Cardiovascular Pharmacology, 16, 910-916.
40. Neutel JM, Black HR, Weber MA (1996) Combination therapy with diuretics: an evolution of understanding. American Journal of Medicine, 101, 61S-70S.